^
    almost4years
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TT16
    4years
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Baylor College of Medicine | Trial completion date: Sep 2038 --> Dec 2038 | Trial primary completion date: Sep 2024 --> Dec 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TT16
    over4years
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jan 2038 --> Sep 2038 | Trial primary completion date: Jan 2024 --> Sep 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TT16
    almost5years
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jan 2037 --> Jan 2038 | Trial primary completion date: Jan 2023 --> Jan 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TT16